Equities research analysts predict that Theravance Biopharma Inc (NASDAQ:TBPH) will report earnings of ($1.18) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Theravance Biopharma’s earnings. The lowest EPS estimate is ($1.25) and the highest is ($1.06). Theravance Biopharma reported earnings of ($1.22) per share in the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The firm is expected to issue its next quarterly earnings results on Tuesday, May 14th.
On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.66) per share for the current year, with EPS estimates ranging from ($5.20) to ($3.47). For the next year, analysts anticipate that the business will post earnings of ($4.63) per share, with EPS estimates ranging from ($6.10) to ($3.35). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.
Several brokerages recently issued reports on TBPH. Cantor Fitzgerald reiterated a “buy” rating and issued a $55.00 price target on shares of Theravance Biopharma in a research note on Tuesday, February 26th. Zacks Investment Research cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday. BidaskClub cut Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, March 9th. Finally, ValuEngine cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $43.40.
In other Theravance Biopharma news, SVP Sharathchandra S. Hegde sold 9,033 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total transaction of $223,205.43. Following the completion of the transaction, the senior vice president now directly owns 270,134 shares in the company, valued at $6,675,011.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in TBPH. Norges Bank acquired a new position in Theravance Biopharma during the fourth quarter valued at approximately $22,422,000. Candriam Luxembourg S.C.A. acquired a new position in Theravance Biopharma during the third quarter valued at approximately $8,321,000. Vanguard Group Inc raised its position in Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc now owns 3,672,030 shares of the biopharmaceutical company’s stock valued at $119,965,000 after purchasing an additional 126,135 shares in the last quarter. Vanguard Group Inc. raised its position in Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc. now owns 3,672,030 shares of the biopharmaceutical company’s stock valued at $119,965,000 after purchasing an additional 126,135 shares in the last quarter. Finally, First Trust Advisors LP acquired a new position in Theravance Biopharma during the fourth quarter valued at approximately $2,243,000. Institutional investors and hedge funds own 84.42% of the company’s stock.
Shares of TBPH stock opened at $22.95 on Tuesday. The company has a debt-to-equity ratio of 6.52, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market capitalization of $1.28 billion, a P/E ratio of -5.75 and a beta of 1.69. Theravance Biopharma has a 1 year low of $21.04 and a 1 year high of $35.48.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
See Also: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.